Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis

Abstract

Gain or loss of catalytic function found in the CYP2C8 gene could certainly alter cerivastatin pharmacokinetics and may influence, at least in part, susceptibility to the development of myotoxicity.